Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas

Sponsor: Vanderbilt-Ingram Cancer Center

Sponsor score: 0

ClinicalTrials ID:NCT04506008

This trial evaluates neoadjuvant hypofractionated radiotherapy followed by surgery for soft tissue sarcoma. It compares ultra-hypofractionation (5 fractions) and moderate hypofractionation (15 fractions) in terms of local control and side effects. Eligible patients have non-retroperitoneal sarcomas and ECOG 0-2. Interventions include radiotherapy, surgical resection, and questionnaires.

Patient Parameters

Program Overview

The trial will use neoadjuvant hypofractionated radiotherapy followed by surgical resection in the treatment for soft tissue sarcoma. It will allow patients to be treated over a shorter course (5 or 15 days of radiation) compared to the traditional 5 week regimen. It is proposed that this will be possible without increasing the risk of wound complication or local recurrence compared with a traditional 5 week course of pre-operative radiation.

Description

Study Objectives:

Primary:

  • To investigate the efficacy of neoadjuvant hypo-fractionated radiotherapy (HRT) followed by surgical resection in the treatment of soft tissue sarcoma (STS) as measured by local control
  • Examine the side effect profile using Radiation Therapy Oncology Group (RTOG) and Common Terminology Criteria for Adverse Events (CTCAE) acute and late side effects criteria and major and minor post-operative complication rates.

OUTLINE: Patients are assigned to 1 of 2 groups by the radiation oncologist.

GROUP I (ULTRA-HYPOFRACTIONATION [UH]): Patients undergo HRT daily for a total of 5 fractions followed by surgery.

GROUP II (MODERATE HYPOFRACTIONATION [MH]): Patients undergo HRT daily for a total of 15 fractions followed by surgery.

After completion of study treatment, patients are followed up within 3 months, then every 3-6 months for a minimum of 2 years.

Eligibility Criteria

Inclusion Criteria

  • Histologic diagnosis of a soft tissue sarcoma of extremity, pelvis, chest wall or trunk/abdominal wall (non-retroperitoneal location)
  • ECOG performance status 0-2
  • Patient must be deemed able to comply with radiation treatment and surgery

Exclusion Criteria

  • History of prior radiation to the same area to be irradiated
  • Pregnancy
  • Active collagen vascular disease or patients genetically predisposed to increased radiation related side effects

Locations

FACILITYZIPCITYSTATE
Vanderbilt-Ingram Cancer Center37232NashvilleTennessee

Get This Program In Your Inbox

You can sign up and apply your patients for this program.